Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Review
. 2022 Mar 18;7(69):eabi4613.
doi: 10.1126/sciimmunol.abi4613. Epub 2022 Mar 18.

Transforming growth factor-β1 in regulatory T cell biology

Affiliations
Review

Transforming growth factor-β1 in regulatory T cell biology

Joshua M Moreau et al. Sci Immunol. .

Abstract

Transforming growth factor-β1 (TGF-β1) is inextricably linked to regulatory T cell (Treg) biology. However, precisely untangling the role for TGF-β1 in Treg differentiation and function is complicated by the pleiotropic and context-dependent activity of this cytokine and the multifaceted biology of Tregs. Among CD4+ T cells, Tregs are the major producers of latent TGF-β1 and are uniquely able to activate this cytokine via expression of cell surface docking receptor glycoprotein A repetitions predominant (GARP) and αv integrins. Although a preponderance of evidence indicates no essential roles for Treg-derived TGF-β1 in Treg immunosuppression, TGF-β1 signaling is crucial for Treg development in the thymus and periphery. Furthermore, active TGF-β1 instructs the differentiation of other T cell subsets, including TH17 cells. Here, we will review TGF-β1 signaling in Treg development and function and discuss knowledge gaps, future research, and the TGF-β1/Treg axis in the context of cancer immunotherapy and fibrosis.

PubMed Disclaimer

Conflict of interest statement

Competing interests: M.D.R. is a consultant and cofounder of TRex Bio Inc. and Sitryx Therapeutics. He is also a consultant for Mozart Therapeutics. Z.L. sits on scientific advisory boards or the board of directors for the following companies: Heat Biologics Inc., Alphamab Oncology (chair), Hengenix Biotech Inc., Ikonisys, Shanghai Henlius Biotech, and the University of Science and Technology of China. Z.L. provides consulting services for Yumed and Houston Methodist Hospital Research Institute. The other authors declare that they have no competing interests.

Figures

Fig. 1.
Fig. 1.. Timeline of notable discoveries on the role of TGF-β1 and TGF-β1 signaling in the biology of T cells and Tregs.
Work on the roles of TGF-β in Treg biology is highlighted in red.
Fig. 2.
Fig. 2.. TGF-β1 biogenesis, activation, and signaling.
TGF-β1 can be produced and secreted by a number of cell types, including Tregs. LTGF-β1 can be secreted in the SLC or LLC form. Upon secretion, the LLC can bind to fibronectin or fibrillin in the ECM. The SLC can bind to cell surface GARP (e.g., on Tregs, platelets, and endothelial cells) or LRRC33 (e.g., on macrophages and microglia). Activation of LTGF-β1 requires cleavage or conformational change of the SLC or LLC, which releases the mature TGF-β1 from the complex or exposes its active binding motif. Active TGF-β1 binds to TGF-βRII on target cells, which recruits and activates TGF-βRI intracellular domain. Phosphorylation of the TGF-β RI cytoplasmic tails leads to activation and signaling via the canonical (Smad-dependent) or noncanonical pathways. All signaling pathways regulate downstream gene expression. TF, transcription factor.
Fig. 3.
Fig. 3.. An integrated view of TGF-β1 in Treg biology.
TGF-β1 is uniquely poised to be a focal point in Treg biology because Tregs highly express the TGF-β receptor, are major producers of latent TGF-β1, and have their activating machinery. (A) Signaling through receptor dimers of TGF-βRI and TGF-βRII is a requirement for both thymic Treg development and induced Treg differentiation. (B) Treg-derived TGF-β1 has long been hypothesized to have a major role in Treg function as these cells are a source of latent TGF-β1 and express both GARP and αvβ8 integrin, which work in tandem to activate TGF-β1. Accumulating evidence suggests that Treg-produced TGF-β1 contributes to immunoregulation but is one of several mechanisms in the Treg arsenal. Although not critical to homeostatic function, Treg generation of bioactive TGF-β1 is likely to have tissue- and context-specific immunomodulatory activity.
Fig. 4.
Fig. 4.. Contributions of TGF-β1 to immune evasion and immunity in cancer.
The pleiotropic roles of TGF-β1 within the TME include (A) dampening the antitumor immune responses, (B) enhancing protumorigenic responses, and (C) promoting other elements of protective immunity through interactions with various cell types. Key functional aspects of these interactions are depicted. DC, dendritic cell; NK, natural killer; IgA, immunoglobulin A; NFκB, nuclear factor κB.

References

    1. de Larco JE, Todaro GJ, Growth factors from murine sarcoma virus-transformed cells. Proc. Natl. Acad. Sci. U.S.A 75, 4001–4005 (1978). - PMC - PubMed
    1. Roberts AB, Anzano MA, Lamb LC, Smith JM, Sporn MB, New class of transforming growth factors potentiated by epidermal growth factor: Isolation from non-neoplastic tissues. Proc. Natl. Acad. Sci. U.S.A 78, 5339–5343 (1981). - PMC - PubMed
    1. Massague J, Czech MP, Iwata K, DeLarco JE, Todaro GJ, Affinity labeling of a transforming growth factor receptor that does not interact with epidermal growth factor. Proc. Natl. Acad. Sci. U.S.A 79, 6822–6826 (1982). - PMC - PubMed
    1. Massague J, Like B, Cellular receptors for type β transforming growth factor: Ligand binding and affinity labeling in human and rodent cell lines. J. Biol. Chem 260, 2636–2645 (1985). - PubMed
    1. Derynck R, Jarrett JA, Chen EY, Eaton DH, Bell JR, Assoian RK, Roberts AB, Sporn MB, Goeddel DV, Human transforming growth factor-β complementary DNA sequence and expression in normal and transformed cells. Nature 316, 701–705 (1985). - PubMed

Publication types

MeSH terms

Substances